NINJA JOINS LA ROCHE-POSAY AS NEW PARTNER IN CAUSE FOR SKIN CANCER DETECTION AND PREVENTION
This unprecedented collaboration comes a year after the 33 years old global icon shared with the world his melanoma diagnosis which was revealed during his annual mole check with a dermatologist.
"By sharing my personal experience far beyond my community, through the campaign with La Roche-Posay, I want to deliver a crucial message about skin cancer prevention: don't play games with detection," said Tyler "NINJA" Blevins, pro-gamer and melanoma survivor.
With an engaged and passionate fanbase across multiple digital platforms, NINJA has transcended the gaming industry, bringing an inclusive and powerful message that resonates with audiences globally.
Tyler "NINJA" Blevins embodies La Roche-Posay's core values of authenticity and transparency, anchoring this cause across multiple generations.
"Together, NINJA and La Roche-Posay are ushering in a new era of skin cancer awareness. With cases rising at an alarming rate,our mission is clear: to educate people about the importance of annual mole checks so that melanoma remains 99% preventable and treatable, especially among younger generations," said Alexandra Reni-Catherine, Global Brand General Manager for La Roche-Posay.
SAVE YOUR SKIN PROGRAMTo ensure a healthier future for all, La Roche-Posay has committed more than 20 years of research and awareness driving campaigns on the prevention and detection of skin cancer. With global initiatives in place to offer annual free mole checks in various communities and education campaigns with Dermatologists on sun safety habits, and self-detection via the ABCDE method. La Roche-Posay remains at the forefront of skin cancer awareness.
40%1 is the projected increase in melanoma rates for today's children by 2040.
99%2 of melanomas are curable if detected early.
70%3 of the population doesn't understand the difference between UVA which penetrates deep and causes aging and UVB which affects the surface and causes sunburn.
80%4 of the total lifetime UV exposure is received before the age of 18.
12%5 only of the global population systematically uses all protective measures during exposure.
200K free mole checks were offered by La Roche-Posay in 2024.
The Save your Skin campaign with NINJA will be launched during the EADV Congress in September 2025 in Paris.
For additional information about La Roche-Posay, visit www.laroche-posay.com and follow La Roche-Posay on Instagram, Tiktok, YouTube and Facebook.
ABOUT LA ROCHE-POSAYIn 2025, La Roche-Posay celebrates 50 years of life-changing dermatological skincare solutions. Created by a pharmacist in 1975, the brand is now present in over 60 countries and is recommended by 100,000 dermatologists worldwide. It provides a unique range of daily skincare developed for every skin type, from newborns to cancer patients, from UV protection to repairing severely fragilized skin.
1 Arnold et al. JAMA Dermatol. 2022;158(5)2 www.skincancer.org3 Passeron. J Eur Acad Dermatol Venereol. 2023;374 Raymond-Lezman JR, Riskin S. Attitudes, Behaviors, and Risks of Sun Protection. Cureus. 2023;15(2):e34934.5 Passeron. J Eur Acad Dermatol Venereol. 2023;37
View original content to download multimedia:https://www.prnewswire.com/news-releases/ninja-joins-la-roche-posay-as-new-partner-in-cause-for-skin-cancer-detection-and-prevention-302408336.html
SOURCE La Roche-Posay
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Global Digital Therapeutics Market Experiencing Rapid Growth at a CAGR of ~28% by 2032 Amid Rising Demand for Personalized Healthcare
The digital therapeutics market is experiencing rapid growth, driven by rising demand for personalized, evidence-based digital health interventions. Increasing prevalence of chronic conditions, mental health issues, and the global push toward remote healthcare are key factors fueling adoption. Regulatory support and integration with traditional healthcare systems are further validating the efficacy of DTx solutions. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ -- DelveInsight's Digital Therapeutics Market Insights report provides the current and forecast market analysis, individual leading digital therapeutics companies' market shares, challenges, digital therapeutics market drivers, barriers, trends, and key digital therapeutics companies such as Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., and others in the market. Digital Therapeutics Overview Digital therapeutics are evidence-based therapeutic interventions delivered through software programs to prevent, manage, or treat medical disorders and diseases. Unlike general wellness apps, digital therapeutics undergo rigorous clinical validation and regulatory review to demonstrate their efficacy, much like traditional pharmaceuticals. These interventions are often used in areas like mental health, chronic disease management (such as diabetes, hypertension, or asthma), and substance use disorders. Delivered via smartphones, tablets, or other digital devices, DTx can be used independently or alongside traditional treatments, offering a scalable, accessible, and often more engaging method of care. One of the key strengths of digital therapeutics is their ability to personalize treatment and provide real-time feedback. By leveraging data analytics, machine learning, and behavioral science, DTx platforms can adapt to individual user needs and track progress continuously. This not only enhances patient engagement but also empowers clinicians with insights to make better-informed decisions. As healthcare systems worldwide face rising costs and increasing demand for chronic care, digital therapeutics offer a promising avenue to improve outcomes, reduce burden on clinical resources, and extend care to underserved populations. Digital Therapeutics Regional Market Insights The global digital therapeutics market is experiencing rapid growth, with notable regional differences driven by healthcare infrastructure, regulatory environments, and technological adoption. North America remains the dominant market, primarily due to strong healthcare reimbursement frameworks, a high prevalence of chronic diseases, and robust digital health ecosystems. The US leads in regulatory clarity, with the FDA approving multiple DTx solutions for conditions like diabetes, insomnia, and mental health. The region also benefits from significant investment activity and partnerships between DTx developers and major pharmaceutical companies. In contrast, Europe is advancing steadily, aided by supportive government initiatives, especially in Germany through its DiGA framework, which allows prescription and reimbursement of certified DTx apps. Scandinavian countries and the UK are also showing strong adoption due to digital-first healthcare strategies. Meanwhile, the Asia-Pacific region is poised for the fastest growth, led by Japan, South Korea, and increasingly, China and India. Factors such as rising smartphone penetration, aging populations, and increasing chronic disease burden are catalyzing adoption. However, regulatory uncertainty and reimbursement limitations continue to pose challenges across emerging markets, requiring targeted policy and infrastructure development to unlock full potential. To know more about why North America is leading the market growth in the digital therapeutics market, get a snapshot of the Digital Therapeutics Market Report Recent Developments in the Digital Therapeutics Market In April 2025, Click Therapeutics, Inc., a pioneer in prescription digital therapeutics and software-enhanced drug therapies, received FDA marketing authorization for the first prescription digital therapeutic designed to prevent episodic migraine. To read more about digital therapeutics for mental health, get a snapshot of the key highlights entailed in the Digital Therapeutics in Mental Health Key Players in the Digital Therapeutics Market The digital therapeutics market has seen a surge in innovation and investment, with several key players emerging as leaders due to their robust pipelines, strong clinical evidence, and strategic partnerships. Companies like Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, Huma, and others have pioneered prescription digital therapeutics across areas such as mental health, ADHD, and chronic disease management. Large tech and pharma companies are also entering the space, accelerating market maturity and broadening DTx applications. These players are not only shaping the competitive landscape but are also influencing regulatory pathways, reimbursement models, and global adoption trends in the digital health ecosystem. Which MedTech key players in the digital therapeutics diabetes are set to emerge as the trendsetter explore @ Digital Therapeutics Behavioral Health Digital Therapeutics Market Key Factor Analysis Digital Therapeutics Market Drivers The growth of the digital therapeutics market is being driven by several key factors. There is a rising demand for remote patient monitoring and mobile health applications, which enable convenient, real-time health management and improve patient engagement outside traditional clinical settings. This trend is further fueled by the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and mental health conditions, which require long-term and continuous care. Additionally, rapid advancements in digital healthcare technologies, including the integration of the Internet of Things (IoT), artificial intelligence (AI), and data analytics, are enhancing the effectiveness and personalization of digital therapeutic solutions, thereby accelerating market adoption. Digital Therapeutics Market Restraints and Challenges The digital therapeutics market faces notable restraints and challenges, primarily revolving around cybersecurity, privacy concerns, and unstable payment models. As digital health solutions increasingly rely on the collection and analysis of sensitive patient data, concerns about data breaches, unauthorized access, and misuse of personal health information pose significant barriers to widespread adoption. Ensuring robust cybersecurity measures and maintaining user trust are critical for the success of these technologies. Additionally, the market is hindered by unstable and evolving payment and reimbursement models. The lack of standardized frameworks for coverage and reimbursement from insurers and healthcare systems creates uncertainty for providers and developers, limiting investment and scalability in the sector. These challenges must be addressed to unlock the full potential of digital therapeutics in modern healthcare. Digital Therapeutics Market Opportunities The digital therapeutics market is witnessing significant growth opportunities, driven by increasing supportive initiatives and strategic alliances among key industry players. Government bodies, healthcare organizations, and regulatory authorities are actively promoting the adoption of digital health solutions through funding, policy support, and streamlined approval processes. At the same time, strategic collaborations between pharmaceutical companies, technology firms, and digital health startups are accelerating product development, expanding market reach, and enhancing therapeutic outcomes. These partnerships are fostering innovation, improving patient engagement, and paving the way for scalable and evidence-based digital interventions across a wide range of chronic and behavioral health conditions. Get a sneak peek at the digital therapeutics FDA approval @ FDA Approved Digital Therapeutics Report Metrics Details Coverage Global Study Period 2022–2032 Digital Therapeutics Market CAGR ~28% Key Digital Therapeutics Companies Limbix Health, Inc., GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc., Pear Therapeutics (US), Inc., CANARY HEALTH, Noom, Inc., Omada Health Inc., Welldoc, Inc., 2Morrow, Inc., ResMed, Teladoc Health, Inc., Fitbit Health Solutions, Huma, and others Digital Therapeutics Market Assessment Digital Therapeutics Market Segmentation Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Interested in knowing the digital therapeutics services? Click to get a snapshot of the Digital Therapeutics Platform Table of Contents 1 Digital Therapeutics Market Report Introduction 2 Digital Therapeutics Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Digital Therapeutics Market Key Factors Analysis 6 Digital Therapeutics Market Porter's Five Forces Analysis 7 Digital Therapeutics Market Layout 8 Digital Therapeutics Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Related Reports Digital Health Market Digital Health Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key digital health companies, including Siemens Healthcare Private Limited, Cisco Systems, Inc., Oracle Cerner, Altera Digital Health Inc., Telefonica, Epic, AT&T, AmerisourceBergen, Candela Corporation., GE Healthcare, Samsung Health, MCKESSON CORPORATION, AliveCor, Inc., Acurable, Amwell, OMRON Healthcare, Inc., Apple Inc., SoftServe, AirStrip Technologies, Inc, Epic Systems Corporation, among others. Telemedicine Service Market Telemedicine Service Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key telemedicine service companies, including Teladoc Health, Inc., MEDICI, American Well, Doximity, Inc., Practo, DocOnline, MeMD®, iCliniq, HealthTap, Inc., WELL Health Technologies Corp., Vesta Teleradiology, Samsung Health U.S, Rudolf Riester GmbH, SHL Telemedicine, Array Behavioral Care, SOC Telemed, Heidelberg Medical Consultancy & Health Tourism Pvt. Ltd., First Derm, DirectDerm, among others. Telehealth Market Telehealth Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key telehealth companies, including Teladoc Health, Inc., Siemens, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, Cerner Corporation, American Well, AMD Global Telemedicine, Joerns Healthcare., GlobalMed, OncoHealth, Allscripts Healthcare, LLC, Derma2go, SOCTelemed, Inc., Honeywell International Inc., Plantronics, Inc., Carium., Emmaus Life Sciences, Inc., Practo, among others. Healthcare Cybersecurity Market Healthcare Cybersecurity Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key healthcare cybersecurity companies, including IBM Corporation, Barracuda Networks, Inc., Forcepoint, Cisco Systems Inc., CrowdStrike Holdings, Inc., Happiest Minds, Palo Alto Networks, Availity, LLC., SentinelOne, HALOCK, Cynerio, KUDELSKI SA, Sophos Ltd., iConnect IT Business Solutions DMCC, illume intelligence, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact UsShruti Thakur info@ +14699457679https:// Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Defibrillator Market worth US$16.44 billion by 2030 with 6.5% CAGR
DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The global Defibrillator Market, valued at US$11.29 billion in 2024, stood at US$11.99 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$16.44 billion by the end of the period. The growth in the defibrillator market is attributed to the increase in the prevalence of cardiovascular diseases, the increasing adult population with higher susceptibility to cardiac arrest, a strong focus of government organizations to enhance the accessibility of defibrillators by boosting the installation of public access defibrillators and providing training & programs on defibrillators. Additionally, the rapid expansion of healthcare infrastructure in emerging countries and strategic collaborations & partnerships among manufacturers to boost the new developments in defibrillators are likely to support the market's growth in the near future. Download PDF Brochure: Browse in-depth TOC on "Defibrillator Market" 337 - Tables57 - Figures296 - Pages By product, the defibrillators market is broadly segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators. The implantable cardioverter defibrillators (ICDs) segment is anticipated to capture the largest global defibrillator market share by product in 2024. Timely intervention using implantable defibrillators during cardiac emergencies is a key advantage offered by this programmed device. Moreover, growing approvals of technologically advanced implantable defibrillators and rising preference for subcutaneous ICDs are likely to support the growth of this segment during the forecast period. By end users, the defibrillators market is segmented into Hospitals & Clinics, Cardiac Centers, Pre-hospital Settings, Public-Access Markets, Home Care Settings, and Other End Users. The hospitals & clinics segment dominated the global defibrillators market in 2024. The significant rise in hospitalization for critical cardiac conditions, the growing number of ICD and CRT-D implant procedures performed in hospitals, and the rising prevalence of cardiac diseases among geriatric patients are the major factors boosting the demand for defibrillators among target end-user segments during the study period. By geography, the defibrillator market is segmented based on the region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the defibrillator market. This can be attributed to the rapid adoption of technologically advanced defibrillators, favorable reimbursement policy, and the strong presence of manufacturers with a strong focus on strengthening R&D through investments in new product development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient pool, government initiatives to modernize & expand healthcare infrastructure, and expansion of market players in the region. Request Sample Pages : Major players in the defibrillator market include Medtronic (Ireland), Stryker (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation (Japan), Boston Scientific Corporation (US), Abbott (US), MicroPort Scientific Corporation (China), Nihon Kohden Corporation (Japan), Biotronik (Germany), and CU Medical Systems, Inc. (South Korea). MEDTRONIC: MEDTRONIC Due to its extensive product portfolio, Medtronic is the leading player in the global implantable defibrillator market. The company primarily focuses on developing innovative products to treat and manage heart failure and heart rhythm disorders. The company focuses on inorganic business growth strategies such as product development & commercialization, acquisitions, and market expansions to strengthen its current position and gain a larger share of the neurovascular devices market. The company received the CE Mark for its implantable defibrillator systems, Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan for managing irregular heart rhythms. Moreover, the company is also focusing on expanding its R&D capabilities to fuel product development and commercialization across mature and emerging markets. Koninklijke Philips N.V. Koninklijke Philips N.V. is a key player in the global defibrillator market, driven by its widely adopted HeartStart AED series. The company has established a strong presence through user-friendly, reliable devices designed for both public and professional use. Philips continues to lead with innovations such as real-time guidance, fast shock delivery, and connected care capabilities. Its strategic focus on accessibility, digital integration, and global deployment has reinforced its role in advancing out-of-hospital cardiac care. Boston Scientific Corporation Boston Scientific Corporation focuses on innovation and product launches in cardiac rhythm management to provide advanced solutions to healthcare professionals to improve the quality of life. The company continuously invests in R&D to launch new & innovative products. Boston Scientific primarily pursues the strategy of new product launches to sustain its position in the global defibrillators market. Regulatory approvals for its MRI-compatible defibrillators and technological advancements are expected to help the company maintain its position in the market. For more information, Inquire Now! Related Reports: Refurbished Medical Equipment Market IoT Medical Devices Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Respiratory Care Devices Market Top 10 Medical Device Technologies Market Get access to the latest updates on Defibrillator Companies and Defibrillator Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
14 hours ago
- Yahoo
InventHelp Inventor Develops Organic Formula to Reduce Pain (HWT-601)
PITTSBURGH, Aug. 13, 2025 /PRNewswire/ -- "I thought there could be an all-organic formula to assist with pain relief and stiffness in various areas of the body," said an inventor, from Rock Creek, Ohio, "so I invented the PAIN AWAY. My formula works quickly to reduce pain, inflammation, and discomfort." The patent-pending invention provides an all-organic formula to aid in the treatment of pain caused by various ailments such as arthritis, back pain, restless leg syndrome, etc. In doing so, it helps relieve pain and discomfort. It also could increase mobility. The invention features an effective formula that is easy to apply so it is ideal for individuals with arthritis, back pain, etc. The original design was submitted to the National sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-HWT-601, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at View original content to download multimedia: SOURCE InventHelp
